Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1123, pseudogene (RNU6-1123P) is a genomic copy of the U6 small nuclear RNA gene, classified as a processed pseudogene. Unlike functional U6 snRNA, which is central to the spliceosome and pre-mRNA splicing in eukaryotes[1][3], RNU6-1123P does not contribute to cellular activity and encodes no proteins. Such pseudogenes are generated by retrotransposition mechanisms, where RNA copies are integrated into the genome but rendered non-functional due to sequence changes or lack of regulatory elements[2][3]. Numerous snRNA pseudogenes are present throughout vertebrate genomes, reflecting retrotransposon activity[2][3]. They play no direct role in cell biology or disease, and have neither clinical nor therapeutic utility. Summary of Key Points: - RNU6-1123P is a non-functional pseudogene, not a receptor or molecular target. - There is nothing to suggest drug relevance, mechanism of action, or biomarker activity. - Its only role is passive: a genomic marker of past retrotransposition events[2]. - It is not considered for therapeutic intervention, nor is it associated with safety concerns[5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1123, pseudogene (RNU6-1123P).